Építés alatt – nem éles oldal
Belépés

NCT06423235Toboroz4. fázis

Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules

Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. márc. 24.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

A multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of Prunella oral liquid in patients with benign thyroid nodules, which belongs to the post-marketing reevaluation clinical study. In this study, 234 subjects will be enrolled by competitive enrollment at several research centers across China. The main inclusion criteria are: ① Thyroid ultrasound examination found thyroid nodules, can be accompanied by goiter, and the nodules meet the following conditions: 1) There were dominant nodules in single or multiple nodules (the largest diameter of the second largest nodules was not more than 50% of the largest nodules), 2) solid nodules, 3) the longest diameter of nodules was ≥1cm and < 3cm, 4) C-TIRADS 3~4A nodules. ② Patients who met the puncture indication were confirmed by fine needle aspiration biopsy (FNAB) as benign nodules (Bethesda II). ③ Levels of TSH, FT3 and FT4 were normal, and the antibody titers of TgAb and TPOAb were normal. Eligible subjects will be randomly assigned on a 1:1:2:2 scale to: Group A (placebo conventional dose group, 10 mL/times, 2 times/day), group B (placebo 2x dose group, 10ml/times, 2 times/day), group C (conventional dose group of Prunella oral liquid), group D (Prunella oral liquid 2x dose group). All subjects will receive the treatment for 9 months and follow up at 3rd, 6th, 9th and 12th month. The primary efficacy endpoint of this study was the rate of change in thyroid nodule volume from baseline at 9 months of treatment. The rate of change in thyroid nodule volume from baseline at 3 and 6 months of treatment was a secondary efficacy endpoint. Other secondary efficacy endpoints included maximum thyroid nodule diameter, number of thyroid nodules, proportion of patients with reduced thyroid nodule volume or ≥50% from baseline, thyroid volume, thyroid function (serum TSH, FT3, FT4, thyroid egg levels (Tg), thyroid antibody levels (TgAb, TPOAb), quality of life evaluation (SF-36), etc. Safety endpoints included incidence of AE/ serious adverse events (SAE), causality, and outcomes. Incidence of AE/SAE leading to discontinuation. Changes in safety laboratory test values from baseline.

Állapot (regiszter)
Toboroz
Fázis (regiszter)
4. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
234 (tervezett)
Első benyújtás
2024. ápr. 7.
Kezdés
2024. júl. 30.
Elsődleges befejezés
2025. júl. 30.
Fő szponzor
Xintian Pharmaceutical
NCT-szám
NCT06423235

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 4. fázis
  • Tervezett résztvevők: 234
  • 2024. júl. 30. és az elsődleges befejezés (2025. júl. 30.) között
  • 22 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Patients who meet the indications for thyroid nodule surgery, such as local compression symptoms obviously related to the nodule, the tumor is located behind the sternum or in the mediastinum, or strongly require surgery due to appearance or ideological concerns affecting normal life;
  • Patients who have had or plan to take thyroid hormone, iodine compound, or antithyroid drug therapy during the study period;
  • Patients who have previously or plan to undergo ablation, neck radiation, surgery and other non-drug treatments during the study period;
  • Persons who are known to be allergic to the investigational drug or its ingredients;

Más betegség

  • Exclude the patients with Deficiency of Yang syndrome, and the following two conditions can be diagnosed: Shortness of breath, abdominal pain and diarrhea, diarrhea with undigested food, Insufficiency with chills, exhaustion and lethargy, pale tongue and white fur, deep and weak pulse
  • Patients with high possibility of thyroid cancer indicated by ultrasonic signs and malignant confirmed by fine needle biopsy;
  • Patients who have taken prunella preparations or other similar Chinese medicines to treat the disease within the past 1 month; Patients using glucocorticoids in the last 3 months;
  • Patients with parathyroid tumor (PTA), medullary thyroid cancer (MTC) or other malignant tumors, or patients with serious cardiovascular disease, liver and kidney disease, osteoporosis, or patients with a history of mental illness;
  • Patients with a family history of thyroid cancer or thyroid cancer syndrome;

Laborértékek

  • Laboratory test index ALT, AST > 1.5 times the upper limit of reference value or blood creatinine (Scr) > the upper limit of reference value;

Egyéb

  • Those who have reproductive needs during pregnancy, lactation and within the last 12 months;
  • Other patients determined by the investigator to be unsuitable for participation in the study.

Kiket keres a vizsgálat

  • 18 years old ≤65 years old;
  • Thyroid ultrasonography found thyroid nodules, may be accompanied by goiter, and the nodules meet the following conditions: 1) single nodules, or dominant nodules in multiple nodules (the largest diameter of the second largest nodules does not exceed 50% of the largest nodules), 2) solid nodules, 3) the longest diameter of nodules ≥1cm and < 3cm, 4) C-TIRADS 3~4A nodules;
  • Patients who met the puncture indications were confirmed by fine needle aspiration biopsy (FNAB) as benign nodules (Bethesda Class II);
  • Serum TSH, free thyroid hormone (FT3, FT4) levels were normal, anti-thyroglobulin (TgAb) and anti-thyroid peroxidase (TPOAb) antibody titers were normal;
  • Meet the diagnostic criteria of thyroid nodules in TCM;
  • Sign the informed consent.

Életkor a regiszterben: 18 év – 65 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (22)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Second Hospital of Army Military Medical UniversityChongqingKínaToboroz
The Second Hospital of Dalian Medical UniversityDalianKínaToboroz
People's Hospital of Guangdong ProvinceGuangzhouKínaToboroz
Zhejiang Province Hospital of Integrated Chinese and Western MedicineHangzhouKínaToboroz
The First Hospital of Kunming Medical UniversityKunmingKínaToboroz
First People's Hospital of Yunnan ProvinceKunmingKínaToboroz
Jiangsu Province Hospital of Integrated Chinese and Western MedicineNanjingKínaToboroz
The First Hospital of Qingdao UniversityQingdaoKínaToboroz
Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of MedicineShanghaiKínaToboroz
Shanghai 10th People's HospitalShanghaiKínaToboroz
Shanghai First People's HospitalShanghaiKínaToboroz
Shanghai Pudong Zhoupu HospitalShanghaiKínaToboroz
People's Hospital of Liaoning ProvinceShenyangKínaToboroz
The First Hospital of China Medical UniversityShenyangKínaToboroz
Hospital of Liaoning University of Chinese MedicineShenyangKínaToboroz
Shenzhen Hospital of Peking UniversityShenzhenKínaToboroz
Shunde Hospital of Southern Medical UniversityShundeKínaToboroz
Weifang People's HospitalWeifangKínaToboroz
Weihai HospitalWeihaiKínaToboroz
Wuhan First HospitalWuhanKínaToboroz
Xiamen Hospital of Traditional Chinese MedicineXiamenKínaToboroz
Xuzhou Medical University HospitalXuzhouKínaToboroz

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.